nach oben

Erschienen in:

19.12.2023 | Original Communication

Genetics screening in an Italian cohort of patients with Amyotrophic Lateral Sclerosis: the importance of early testing and its implication

verfasst von: Laura Libonati, Chiara Cambieri, Davide Colavito, Federica Moret, Edoardo D’Andrea, Elda Del Giudice, Alberta Leon, Maurizio Inghilleri, Marco Ceccanti

Erschienen in: Journal of Neurology | Ausgabe 4/2024

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease with an elusive etiology. While environmental factors have been considered, familial ALS cases have raised the possibility of genetic involvement. This genetic connection is increasingly evident, even in patients with sporadic ALS. We allowed access to the genetic test to all patients attending our clinic to identify the prevalence and the role of genetic variants in the development of the disease and to identify patients with potentially treatable forms of the disease.

Materials and methods

194 patients with probable or definite ALS, were enrolled. A comprehensive genetic testing was performed, including sequencing all exons of the SOD1 gene and testing for hexanucleotide intronic repeat expansions (G4C2) in the C9orf72 gene using fluorescent repeat-primed PCR (RP-PCR). Whole Exome NGS Sequencing (WES) was performed, followed by an in silico multigene panel targeting neuromuscular diseases, spastic paraplegia, and motor distal neuropathies. We conducted statistical analyses to compare different patient groups.

Results

Clinically significant pathogenetic variants were detected in 14.43% of cases. The highest prevalence of pathogenetic variants was observed in fALS patients, but a substantial proportion of sALS patients also displayed at least one variant, either pathogenetic or of uncertain significance (VUS). The most observed pathogenetic variant was the expansion of the C9orf72 gene, which was associated with a shorter survival. SOD1 variants were found in 1.6% of fALS and 2.5% of sALS patients.

Discussion

The study reveals a significant number of ALS patients carrying pathogenic or likely pathogenic variants, with a higher prevalence in familial ALS cases. The expansion of the C9orf72 gene emerges as the most common genetic cause of ALS, affecting familial and sporadic cases. Additionally, SOD1 variants are detected at an unexpectedly higher rate, even in patients without a familial history of ALS, underscoring the crucial role of genetic testing in treatment decisions and potential participation in clinical trials. We also investigated variants in genes such as TARDBP, FUS, NEK1, TBK1, and DNAJC7, shedding light on their potential involvement in ALS. These findings underscore the complexity of interpreting variants of uncertain significance (VUS) and their ethical implications in patient communication and genetic counseling for patients' relatives.

Conclusion

This study emphasizes the diverse genetic basis of ALS and advocates for integrating comprehensive genetic testing into diagnostic protocols. The evolving landscape of genetic therapies requires identifying all eligible patients transcending traditional familial boundaries. The presence of VUS highlights the multifaceted nature of ALS genetics, prompting further exploration of complex interactions among genetic variants, environmental factors, and disease development.

Nur mit Berechtigung zugänglich

Brown RH, Al-Chalabi A (2017) Amyotrophic lateral sclerosis. N Engl J Med 377(2):162–172PubMedCrossRef

Chiò A et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41(2):118–130PubMedCrossRef

Al-Chalabi A, Hardiman O (2013) The epidemiology of ALS: a conspiracy of genes, environment and time. Nat Rev Neurol 9(11):617–628PubMedCrossRef

Kiernan MC et al (2011) Amyotrophic lateral sclerosis. Lancet (London, England) 377(9769):942–955PubMedCrossRef

Pender N, Pinto-Grau M, Hardiman O (2020) Cognitive and behavioural impairment in amyotrophic lateral sclerosis. Curr Opin Neurol 33(5):649–654PubMedCrossRef

Wang M-D et al (2017) Identification of risk factors associated with onset and progression of amyotrophic lateral sclerosis using systematic review and meta-analysis. Neurotoxicology 61:101–130PubMedCrossRef

Qiu X-B et al (2006) The diversity of the DnaJ/Hsp40 family, the crucial partners for Hsp70 chaperones. Cell Mol Life Sci: CMLS 63(22):2560–2570PubMedCrossRef

Kurland LT, Mulder DW (1955) Epidemiologic investigations of amyotrophic lateral sclerosis. 2. Familial aggregations indicative of dominant inheritance. I Neurol 5(3):182–196

Perrone B, Conforti FL (2020) Common mutations of interest in the diagnosis of amyotrophic lateral sclerosis: how common are common mutations in ALS genes? Expert Rev Mol Diagn 20(7):703–714PubMedCrossRef

10.

Chia R, Chiò A, Traynor BJ (2018) Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications. Lancet Neurol 17(1):94–102PubMedCrossRef

11.

Wroe R et al (2008) ALSOD: the amyotrophic lateral sclerosis online database. Amyotroph Lateral Scler: Off Publ World Fed Neurol Res Group Motor Neuron Dis 9(4):249–250CrossRef

12.

Renton AE, Chiò A, Traynor BJ (2014) State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci 17(1):17–23PubMedCrossRef

13.

Cooper-Knock J, Shaw PJ, Kirby J (2014) The widening spectrum of C9ORF72-related disease; genotype/phenotype correlations and potential modifiers of clinical phenotype. Acta Neuropathol 127(3):333–345PubMedPubMedCentralCrossRef

14.

Al-Chalabi A et al (2010) An estimate of amyotrophic lateral sclerosis heritability using twin data. J Neurol Neurosurg Psychiatry 81(12):1324–1326PubMedCrossRef

15.

Al-Chalabi A, Lewis CM (2011) Modelling the effects of penetrance and family size on rates of sporadic and familial disease. Hum Hered 71(4):281–288PubMedCrossRef

16.

Al-Chalabi A, van den Berg LH, Veldink J (2017) Gene discovery in amyotrophic lateral sclerosis: implications for clinical management. Nat Rev Neurol 13(2):96–104PubMedCrossRef

17.

Al-Chalabi A et al (2014) Analysis of amyotrophic lateral sclerosis as a multistep process: a population-based modelling study. Lancet Neurol 13(11):1108–1113PubMedPubMedCentralCrossRef

18.

Vucic S et al (2020) ALS is a multistep process in South Korean, Japanese, and Australian patients. Neurology 94(15):e1657–e1663PubMedPubMedCentralCrossRef

19.

Miller T et al (2020) Phase 1–2 trial of antisense oligonucleotide tofersen for SOD1 ALS. N Engl J Med 383(2):109–119PubMedCrossRef

20.

Salmon K et al (2022) The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis. Brain J Neurol 145(4):1207–1210CrossRef

21.

Shepheard SR et al (2021) Value of systematic genetic screening of patients with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 92(5):510–518PubMedCrossRef

22.

Brooks BR et al (2000) El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord: Off Publ World Fed Neurol, Res Group Motor Neuron Dis 1(5):293–299CrossRef

23.

Byrne S et al (2011) Proposed criteria for familial amyotrophic lateral sclerosis. Amyotroph Lateral Scler 12(3):157–159PubMedCrossRef

24.

Paulson H (2018) Repeat expansion diseases. Handb Clin Neurol 147:105–123PubMedPubMedCentralCrossRef

25.

van Blitterswijk M et al (2012) Evidence for an oligogenic basis of amyotrophic lateral sclerosis. Hum Mol Genet 21(17):3776–3784PubMedCrossRef

26.

Shibuya K et al (2021) Facial onset amyotrophic lateral sclerosis with K3E variant in the Cu/Zn superoxide dismutase gene. Amyotroph Lateral Scler Frontotemporal Degener 22(1–2):144–146PubMedCrossRef

27.

Chen LX et al (2021) SOD1 mutation spectrum and natural history of ALS patients in a 15-year cohort in Southeastern China. Front Genet 12:746060PubMedPubMedCentralCrossRef

28.

Pang SY et al (2017) Burden of rare variants in ALS genes influences survival in familial and sporadic ALS. Neurobiol Aging 58:238.e9-238.e15PubMedCrossRef

29.

Tasca G et al (2020) SOD1 p.D12Y variant is associated with amyotrophic lateral sclerosis/distal myopathy spectrum. Eur J Neurol 27(7):1304–1309PubMedCrossRef

30.

Weber M et al (2012) ALS patients with SOD1 mutations in Switzerland show very diverse phenotypes and extremely long survival. J Neurol Neurosurg Psychiatry 83(3):351–353PubMedCrossRef

31.

Chiò A et al (2010) Amyotrophic lateral sclerosis-frontotemporal lobar dementia in 3 families with p.Ala382Thr TARDBP mutations. Arch Neurol 67(8):1002–1009PubMedPubMedCentralCrossRef

32.

Quadri M et al (2011) Broadening the phenotype of TARDBP mutations: the TARDBP Ala382Thr mutation and Parkinson’s disease in Sardinia. Neurogenetics 12(3):203–209PubMedPubMedCentralCrossRef

33.

Tunca C et al (2020) Revisiting the complex architecture of ALS in Turkey: expanding genotypes, shared phenotypes, molecular networks, and a public variant database. Hum Mutat 41(8):e7–e45PubMedCrossRef

34.

Kenna KP et al (2016) NEK1 variants confer susceptibility to amyotrophic lateral sclerosis. Nat Genet 48(9):1037–1042PubMedPubMedCentralCrossRef

35.

Zhang L et al (2004) GC/AT-content spikes as genomic punctuation marks. Proc Natl Acad Sci 101(48):16855–16860PubMedPubMedCentralCrossRef

36.

Dilliott AA et al (2022) DnaJC7 in amyotrophic lateral sclerosis. Int J Mol Sci 23(8):4076PubMedPubMedCentralCrossRef

37.

Farhan SMK et al (2019) Exome sequencing in amyotrophic lateral sclerosis implicates a novel gene, DNAJC7, encoding a heat-shock protein. Nat Neurosci 22(12):1966–1974PubMedPubMedCentralCrossRef

38.

Azzedine H et al (2013) PLEKHG5 deficiency leads to an intermediate form of autosomal-recessive Charcot-Marie-Tooth disease. Hum Mol Genet 22(20):4224–4232PubMedPubMedCentralCrossRef

39.

Karch CM et al (2016) Missense mutations in progranulin gene associated with frontotemporal lobar degeneration: study of pathogenetic features. Neurobiol Aging 38:215.e1-215.e12PubMedCrossRef

40.

Stevanin G et al (2007) Mutations in SPG11, encoding spatacsin, are a major cause of spastic paraplegia with thin corpus callosum. Nat Genet 39(3):366–372PubMedCrossRef

41.

D’Amore A et al (2018) Next generation molecular diagnosis of hereditary spastic paraplegias: an Italian cross-sectional study. Front Neurol 9:981PubMedPubMedCentralCrossRef

42.

Richards S et al (2015) Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology. Genet Med 17(5):405–423PubMedPubMedCentralCrossRef

43.

Grassano M et al (2022) Systematic evaluation of genetic mutations in ALS: a population-based study. J Neurol Neurosurg Psychiatry 93(11):1190–1193PubMedCrossRef

44.

Mehta PR et al (2019) Younger age of onset in familial amyotrophic lateral sclerosis is a result of pathogenic gene variants, rather than ascertainment bias. J Neurol Neurosurg Psychiatry 90(3):268–271PubMedCrossRef

45.

Beckers J, Tharkeshwar AK, Van Damme P (2021) C9orf72 ALS-FTD: recent evidence for dysregulation of the autophagy-lysosome pathway at multiple levels. Autophagy 17(11):3306–3322PubMedPubMedCentralCrossRef

46.

Chiò A et al (2012) ALS/FTD phenotype in two Sardinian families carrying both C9ORF72 and TARDBP mutations. J Neurol Neurosurg Psychiatry 83(7):730–733PubMedCrossRef

47.

Kaivorinne AL et al (2014) Novel TARDBP sequence variant and C9ORF72 repeat expansion in a family with frontotemporal dementia. Alzheimer Dis Assoc Disord 28(2):190–193PubMedPubMedCentralCrossRef

48.

van Blitterswijk M et al (2013) C9ORF72 repeat expansions in cases with previously identified pathogenic mutations. Neurology 81(15):1332–1341PubMedPubMedCentralCrossRef

49.

King A et al (2013) Mixed tau, TDP-43 and p62 pathology in FTLD associated with a C9ORF72 repeat expansion and p.Ala239Thr MAPT (tau) variant. Acta Neuropathol 125(2):303–310PubMedCrossRef

50.

Millecamps S et al (2012) Phenotype difference between ALS patients with expanded repeats in C9ORF72 and patients with mutations in other ALS-related genes. J Med Genet 49(4):258–263PubMedCrossRef

51.

Cooper-Knock J et al (2012) Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72. Brain 135(Pt 3):751–764PubMedPubMedCentralCrossRef

52.

Testi S et al (2015) Co-occurrence of the C9ORF72 expansion and a novel GRN mutation in a family with alternative expression of frontotemporal dementia and amyotrophic lateral sclerosis. J Alzheimers Dis 44(1):49–56PubMedCrossRef

53.

Umoh ME et al (2016) Comparative analysis of C9orf72 and sporadic disease in an ALS clinic population. Neurology 87(10):1024–1030PubMedPubMedCentralCrossRef

54.

Bernard E et al (2020) Clinical and molecular landscape of ALS patients with SOD1 mutations: novel pathogenic variants and novel phenotypes. A single ALS center study. Int J Mol Sci 21(18):6807PubMedPubMedCentralCrossRef

55.

Olsen CG et al (2022) Genetic epidemiology of amyotrophic lateral sclerosis in Norway: a 2-year population-based study. Neuroepidemiology 56(4):271–282PubMedCrossRef

56.

Gagliardi D et al (2023) Clinical and molecular features of patients with amyotrophic lateral sclerosis and. Front Neurol 14:1169689PubMedPubMedCentralCrossRef

57.

Opie-Martin S et al (2022) The SOD1-mediated ALS phenotype shows a decoupling between age of symptom onset and disease duration. Nat Commun 13(1):6901PubMedPubMedCentralCrossRef

58.

Deshaies J-E et al (2018) TDP-43 regulates the alternative splicing of hnRNP A1 to yield an aggregation-prone variant in amyotrophic lateral sclerosis. Brain J Neurol 141(5):1320–1333CrossRef

59.

Ishiguro A et al (2020) Molecular dissection of ALS-linked TDP-43 - involvement of the Gly-rich domain in interaction with G-quadruplex mRNA. FEBS Lett 594(14):2254–2265PubMedCrossRef

60.

Kabashi E et al (2010) Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet 19(4):671–683PubMedCrossRef

61.

Chiang H-H et al (2012) Novel TARDBP mutations in Nordic ALS patients. J Hum Genet 57(5):316–319PubMedCrossRef

62.

Naruse H et al (2021) Loss-of-function variants in NEK1 are associated with an increased risk of sporadic ALS in the Japanese population. J Hum Genet 66(3):237–241PubMedCrossRef

63.

Kim G et al (2020) ALS genetics: gains, losses, and implications for future therapies. Neuron 108(5):822–842PubMedPubMedCentralCrossRef

64.

Yao L et al (2021) NEK1 mutations and the risk of amyotrophic lateral sclerosis (ALS): a meta-analysis. Neurol Sci 42(4):1277–1285PubMedCrossRef

65.

Riva N et al (2022) Variants in a Cohort of Italian patients with amyotrophic lateral sclerosis. Front Neurosci 16:833051PubMedPubMedCentralCrossRef

66.

Bánfai Z et al (2017) Novel phenotypic variant in the MYH7 spectrum due to a stop-loss mutation in the C-terminal region: a case report. BMC Med Genet 18(1):105PubMedPubMedCentralCrossRef

67.

Lu Y, Almeida S, Gao F-B (2021) TBK1 haploinsufficiency in ALS and FTD compromises membrane trafficking. Acta Neuropathol 142(1):217–221PubMedPubMedCentralCrossRef

68.

Libonati L et al (2022) A novel homozygous mutation in TBK1 gene causing ALS-FTD. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol 43(3):2101–2104

69.

An H et al (2019) ALS-linked FUS mutations confer loss and gain of function in the nucleus by promoting excessive formation of dysfunctional paraspeckles. Acta Neuropathol Commun 7(1):7PubMedPubMedCentralCrossRef

70.

Grassano M et al (2022) Phenotype analysis of fused in sarcoma mutations in amyotrophic lateral sclerosis. Neurol Genet 8(5):e200011PubMedPubMedCentralCrossRef

71.

Groen EJ et al (2010) FUS mutations in familial amyotrophic lateral sclerosis in the Netherlands. Arch Neurol 67(2):224–230PubMedCrossRef

72.

Abramzon YA et al (2020) The overlapping genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Front Neurosci 14:42PubMedPubMedCentralCrossRef

73.

Kirola L, Mukherjee A, Mutsuddi M (2022) Recent updates on the genetics of amyotrophic lateral sclerosis and frontotemporal dementia. Mol Neurobiol 59(9):5673–5694PubMedCrossRef

74.

Tohnai G et al (2021) Mutation screening of the DNAJC7 gene in Japanese patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging 113:131–136PubMedCrossRef

75.

Jih K-Y et al (2020) Rapid progressive ALS in a patient with a DNAJC7 loss-of-function mutation. Neurol Genet 6(5):e503PubMedPubMedCentralCrossRef

76.

Miao Y et al (2021) related autosomal recessive lower motor neuron disease with dysmyelination in peripheral nerves. Clin Neuropathol 40(6):328–332PubMedCrossRef

77.

Kim HJ et al (2013) Mutations in the PLEKHG5 gene is relevant with autosomal recessive intermediate Charcot-Marie-Tooth disease. Orphanet J Rare Dis 8:104PubMedPubMedCentralCrossRef

78.

Maystadt I et al (2007) The nuclear factor kappaB-activator gene PLEKHG5 is mutated in a form of autosomal recessive lower motor neuron disease with childhood onset. Am J Hum Genet 81(1):67–76PubMedPubMedCentralCrossRef

79.

Fenoglio C et al (2009) Rs5848 variant influences GRN mRNA levels in brain and peripheral mononuclear cells in patients with Alzheimer’s disease. J Alzheimer’s Dis: JAD 18(3):603–612PubMedCrossRef

80.

Cruchaga C et al (2009) Cortical atrophy and language network reorganization associated with a novel progranulin mutation. Cereb Cortex (New York, NY, 1991) 19(8):1751–1760CrossRef

81.

Wang J et al (2010) Pathogenic cysteine mutations affect progranulin function and production of mature granulins. J Neurochem 112(5):1305–1315PubMedCrossRef

82.

Steele NZ et al (2018) Frequency of frontotemporal dementia gene variants in C9ORF72, MAPT, and GRN in academic versus commercial laboratory cohorts. Adv Genom Genet 8:23–33CrossRef

Titel: Genetics screening in an Italian cohort of patients with Amyotrophic Lateral Sclerosis: the importance of early testing and its implication
verfasst von: Laura Libonati
Chiara Cambieri
Davide Colavito
Federica Moret
Edoardo D’Andrea
Elda Del Giudice
Alberta Leon
Maurizio Inghilleri
Marco Ceccanti
Publikationsdatum: 19.12.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Neurology / Ausgabe 4/2024
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI: https://doi.org/10.1007/s00415-023-12142-x

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Nicht Creutzfeldt Jakob, sondern Abführtee-Vergiftung

29.05.2024 Hyponatriämie Nachrichten

Eine ältere Frau trinkt regelmäßig Sennesblättertee gegen ihre Verstopfung. Der scheint plötzlich gut zu wirken. Auf Durchfall und Erbrechen folgt allerdings eine Hyponatriämie. Nach deren Korrektur kommt es plötzlich zu progredienten Kognitions- und Verhaltensstörungen.

Schutz der Synapsen bei Alzheimer

29.05.2024 Morbus Alzheimer Nachrichten

Mit einem Neurotrophin-Rezeptor-Modulator lässt sich möglicherweise eine bestehende Alzheimerdemenz etwas abschwächen: Erste Phase-2-Daten deuten auf einen verbesserten Synapsenschutz.

Sozialer Aufstieg verringert Demenzgefahr

24.05.2024 Demenz Nachrichten

Ein hohes soziales Niveau ist mit die beste Versicherung gegen eine Demenz. Noch geringer ist das Demenzrisiko für Menschen, die sozial aufsteigen: Sie gewinnen fast zwei demenzfreie Lebensjahre. Umgekehrt steigt die Demenzgefahr beim sozialen Abstieg.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Introduction

Materials and methods

Results

Discussion

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2024

Late-onset multiple sclerosis: disability trajectories in relapsing–remitting patients of the Italian MS Registry

Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort

Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials

Myelitis as a side effect of tofersen therapy in SOD1-associated ALS

Cognitive phenotypes in multiple sclerosis: mapping the spectrum of impairment